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012.06.00Abstract Background: Lupus nephritis (LN) is one of the most severe complications of SLE. SLE
patients have a greater risk of developing premature atherosclerosis. Resistin is an adipocyte-
secreted peptide. It has pro-inﬂammatory and atherogenic effects.
Aim of the work: To assess the serum levels of resistin in SLE patients and to evaluate it as a
marker of nephritis and premature atherosclerosis.
Patients and methods: This study included 50 SLE nonpregnant female adult (mean age
23.1 ± 6.9 years) patients as well as 40 healthy volunteers matched in age and sex as a control
group. Serum levels of resistin were assayed using enzyme-linked immunosorbent assay (ELISA).
All patients and controls underwent laboratory investigations and carotid duplex. Disease activity
was assessed using SLE Disease Activity Index (SLEDAI). Renal biopsy was performed for SLE
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138 H. Elshishtawy et al.Results: There was a highly statistically signiﬁcant increase in mean serum resistin levels
(14.1 ± 3.88 ng/ml) in patients versus the control group (6.44 ± 1.34 ng/ml) being more obvious
in those with LN. Resistin had a signiﬁcant positive correlation with markers of inﬂammation,
SLEDAI and carotid intima media thickness (CIMT).
Conclusion: Serum level of resistin may serve as a marker of LN and atherosclerosis in SLE
patients. A more aggressive control of the underlying inﬂammatory process along with the control
of traditional risk factors (hypertension and cholesterol) may be beneﬁcial in reducing the risk fac-
tors of renal and atherosclerotic involvement in SLE. Therapeutic approaches with drugs that target
resistin might be useful in the treatment of SLE.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is a chronic inﬂammatory
disease that occurs predominantly in women [1]. Lupus nephri-
tis (LN) is one of the most severe complications of SLE, affect-
ing 50% of patients and accounting for signiﬁcant morbidity
and mortality [2]. Individuals with SLE have a greater risk
of developing premature atherosclerotic cardiovascular disease
(ASCVD) than the general population [3].
Adipose tissue has endocrine functions and is the main
source of several mediators, termed adipocytokines, which in-
clude resistin, leptin, visfatin and adiponectin. Adipose tissue
has become a subject of intensive research for its ability to se-
crete numerous hormones and cytokines with important sys-
temic metabolic effects. It has been demonstrated that
adipocytes and other cell types residing in adipose tissue such
as immunocompetent cells contribute to its overall endocrine
production [4].
Resistin was originally described as an adipocyte-secreted
peptide. Resistin is a 12.5 kDa cysteine-rich protein that con-
sists of 108 amino acids in humans and 114 amino acids in
mice, including a 17-amino acid signal peptide, a variable re-
gion of 37 amino acids, and a conserved C terminus [5]. These
adipocytokines have profound effects on glucose homeostasis,
appetite regulation, inﬂammation and atherosclerosis [6]. Res-
istin has pro-inﬂammatory and atherogenic effects and is asso-
ciated with insulin resistance. It has been proclaimed to be
associated with obesity and diabetes. Circulating serum resistin
levels were found to be elevated proportionally to the degree of
obesity [41]. Elevated resistin levels have been associated with
decreased glomerular ﬁltration rate (GFR) and inﬂammation
[7]. Animal studies show that resistin is produced mainly in
the white adipose tissue and may be the linkage between obes-
ity and insulin resistance. In humans, the role of resistin is not
yet fully established. There is evidence that resistin has proin-
ﬂammatory properties and is abundant in inﬂammatory dis-
eases like rheumatoid arthritis (RA) [8] and Crohn’s disease
[9] and also is associated with inﬂammatory markers in several
different populations [10]. In humans, resistin is expressed in
inﬂammatory cells, leukocytes, and macrophages and has the
potency of inducing production of interleukin (IL)-6 and tu-
mor necrosis factor-alpha (TNF-a) [11].
Increased serum resistin has also been measured in patients
with chronic renal failure and end stage renal disease, suggest-
ing that renal functions are an important factor in regulating
the systemic levels of resistin [12]. Chronic kidney disease
(CKD) alone has been reported to be a risk factor for athero-
sclerosis and cardiovascular complications, due to concurrentinﬂammation and endothelial dysfunction. In patients without
CKD, resistin has been related to inﬂammatory markers and
coronary artery disease. Moreover, resistin up-regulates adhe-
sion molecules and may be linked to cardiovascular disease in
the metabolic syndrome [13].
Recent studies show that even mild renal dysfunction is
associated with an increased risk of cardiovascular disease
(CVD). Patients with CKD have risk increased for morbidity
and mortality from CVD and considered as potential candi-
dates for aggressive risk factor reduction [14]. Possible roles
for resistin in obesity-related subclinical inﬂammation, athero-
sclerosis and cardiovascular disease, non-alcoholic fatty liver
disease, rheumatic diseases, malignant tumors, asthma, inﬂam-
matory bowel disease, and chronic kidney disease have already
been demonstrated. In addition, resistin can modulate several
molecular pathways involved in metabolic, inﬂammatory,
and autoimmune diseases [15].
The aim of this study was to assess the serum levels of res-
istin in SLE patients and to evaluate its role as a marker of
nephritis and premature atherosclerosis in SLE patients.
2. Patients and methods
This was a cross sectional study that included 50 SLE nonpreg-
nant adult female patients who attended the outpatient clinics
of Rheumatology & Rehabilitation and Internal medicine
Departments of Ain Shams University Hospitals. SLE was
diagnosed according to the criteria of American College of
Rheumatology [16]. Forty healthy nonpregnant volunteers
matching in age, sex and BMI served as a control group. It
was prerequisite to have the control matched in BMI because
resistin is associated with obesity [41]. Written informed con-
sent was obtained from every patient and control. The study
was approved by Ain Shams medical ethics committee.
Exclusion criteria: Pregnancy, diabetes mellitus, malignan-
cies, overlap syndrome, liver disease, inﬂammatory bowel dis-
ease, patients with history of angina, myocardial infarction or
stroke and patients on hemodialysis were excluded from the
study. Diabetes was excluded because it is a well known risk
factor for atherosclerosis. Patients with clinical manifesta-
tions of angina, myocardial infarction or stroke were ex-
cluded. But patients with subclinical atherosclerosis
(dyslipedemia) were included in the study. Hypertension
was not excluded because some of the traditional risk factors
for atherosclerosis including (hypertension or hyperlipidemia)
may result from or be exacerbated by SLE and/or therapeutic
intervention (steroids intake). Also isolated hypertension out-
side of the norms for age and gender raises suspicion of the
Resistin in systemic lupus erythematosus: Relation to lupus nephritis and premature atherosclerosis 139underlying renal disease. So, it is most probably this is a sec-
ondary hypertension [42].
Clinical assessment: Full medical history taking with stress
on disease duration, drug history and history of traditional
cardiovascular risk factors.
Thorough clinical examination which included the
following
– BMI (kg/m2) was determined by weight (kg) and height (m).
– Measurement of blood pressure: hypertension was deﬁned
as systolic blood pressure P140 mm Hg or diastolic blood
pressure P90 mm Hg on 2 consecutive settings.
Laboratory tests included:
– Complete blood picture.
– Erythrocyte sedimentation rate (ESR) using Westergren
method.
– CRP using latex agglutination method.
– Autoantibodies measurement: anti-nuclear antibody and
anti-dsDNA.
– Kidney function tests: Creatinine using SynchcronCX5,
urine analysis, 24-hour urine collection for protein assay
and glomerular ﬁltration rate.
– Lupus nephritis: was diagnosed if there was persistent pro-
teinuria (more than 0.5 g/24 h or more than 3+ by urine
dipstick test) and/or cellular casts in urine (red blood cell,
hemoglobin, granular, tubular or mixed).
– Serum complements C3 and C4 assessed by nephelometry.
– Total cholesterol, low density lipoprotein (LDL), high den-
sity lipoprotein (HDL) and triglycerides levels were mea-
sured in fasting samples using standardized laboratory tests.
– We used a modiﬁed version of the World Health Organiza-
tion (WHO) deﬁnition for diagnosis of metabolic syn-
drome. The modiﬁed WHO deﬁnition requires, elevated
triglycerides P150 mg/dl or HDL <40 mg/dl in women,
and high blood pressure, deﬁned as P140/90 mm Hg or
the use of hypertensive medications [38].
– Measurement of serum resistin was done by enzyme linked
immunosorbent assay (ELISA). The kits were supplied
from BioVendor – Laboratornı´ medicı´na a.s (European
Union). Samples are incubated in microplate wells pre-
coated with polyclonal anti-human resistin antibody. After
60 min incubation and washing, biotin-labeled second poly-
clonal anti-human resistin antibody is added and incubated
with captured resistin for 60 min. After another washing,
streptavidin–HRP conjugate is added. After 60 min incuba-
tion and the last washing step, the remaining conjugate is
allowed to react with the substrate solution (TMB). The
reaction is stopped by the addition of acidic solution and
absorbance of the resulting yellow product is measured.
The absorbance is proportional to the concentration of res-
istin. A standard curve is constructed by plotting absor-
bance values against concentrations of Standards, and
concentrations of unknown samples are determined using
this standard curve.
Assessment of the disease activity using SLE disease activity
index (SLEDAI): SLEDAI is a validated model of experienced
clinicians’ global assessments of disease activity in SLE pa-
tients. Patients are considered to be with active disease for 8
or more points [17].Systemic Lupus International Collaborating Clinics
(SLICC) was not included because our study was a cross sec-
tional one without new drug trial [43].
An ultrasound-guided renal biopsy was performed, after
obtaining a written consent, for all SLE with nephritis pa-
tients using a 16-gauge coaxial quick-core biopsy set. Light
microscopy, electron microscopy and immunohistochemical
staining were performed. Histopathological features of LN
were classiﬁed by means of the International Society of
Nephrology/Renal Pathology Society (ISN/RPS) classiﬁca-
tion of LN [18].
Carotid duplex sonography (GE logic 7). All patients and
controls underwent extracranial carotid arteries assessment
by high-resolution B-mode ultrasound. The ultrasonographic
scan protocol was used to measure intima-media thickness
(IMT) in the common carotid artery in mm and detection of
atheromatous plaques if present. A cut off value of 0.9 mm
was taken for carotid intima media thickness (CIMT) [39]. Pa-
tients who had CIMT above this value or metabolic syndrome
were considered to have atherosclerosis in a subclinical stage
[40].
Statistical analysis: Analysis of data was performed by IBM
computer using statistical package for social science (SPSS)
version 16. Data were expressed as mean, standard deviation,
and range. Number and percentage were used to describe qual-
itative variables. The comparison between two groups with
parametric variables was done using independent sample t-test
(t), while the comparison between two groups with nonpara-
metric variables was done using Mann–Whitney test (z). The
correlation coefﬁcient between two parametric parameters
was calculated by using Pearson correlation coefﬁcient; while
the correlation coefﬁcient between two nonparametric param-
eters was calculated by using Spearman correlation. Partial
correlation was done to describe the relationship between
two variables while adjusting for the effects of one or more
other variables. In all tests if (p> 0.05) it is nonsigniﬁcant,
if (p< 0.05) it is signiﬁcant and if (p< 0.001) it is highly
signiﬁcant.3. Results
Patients’ clinical, laboratory and carotid duplex data: Pa-
tients’ clinical, laboratory and carotid duplex data are shown
in Table 1. Fifty patients (100%) had mucocutaneous mani-
festations, 3 patients (6%) had serositis, 29 (58%) had arthri-
tis. Disease activity was assessed by SLEDAI. There were 27
patients (54%) with active SLE. Concerning renal manifesta-
tions, 32 patients had LN (64%), 9 patients were class II
(18%), 8 patients were class III (16%), 11 patients were class
IV (22%) and 4 patients were class V (8%), Figs. 3–6. Twelve
patients (24%) had CIMP >0.9 mm, none of our patients
had plaque, Fig. 7. Thirteen patients (26%) had subclinical
atherosclerosis. Fifty patients (100%) received steroids, 8
(16%) received hydroxychloroquine, 5 (10%) received azathi-
oprine, 11 (22%) received cyclophosphamide.
Comparison between patients and control groups as regards
clinical, laboratory and carotid duplex: There was a statistically
highly signiﬁcant increase as regards ESR, CRP, creatinine,
cholesterol, LDL, triglycerides and resistin in the SLE patients
versus the control group (p< 0.001). There was a statistically
signiﬁcant increase in CIMT in patients versus the control
Table 1 Patients’ clinical, laboratory, carotid duplex exami-
nation data.
Parameter Range Mean ± SD
Min. Max.
Age (years) 14 42 23.06 ± 6.92
Disease duration (years) 0.25 4.0 2.29 ± 1.25
Systolic (mm Hg) 100 170 126.40 ± 17.53
Diastolic (mm Hg) 70 100 80.90 ± 8.90
BMI (kg/m2) 26.3 29.2 27.60 ± 0.83
Steroid dose (mg) 5 60 19.90 ± 16.68
Steroid duration (years) 0.25 4 1.88 ± 1.16
ESR (mm/h) 27 115 56.74 ± 25.35
CRP (mg/dl) 8 24 12.76 ± 3.87
Hb% (g/dl) 5.2 11.8 8.76 ± 2.12
RBC (106/mm3) 1.9 5.5 4.33 ± 2.35
WBC (103/mm3) 2.3 10.2 5.17 ± 2.69
Platelet (103/mm3) 110 400 254.62 ± 74.61
Creatinine (mg/dl) 0.6 3.8 1.69 ± 1.09
GFR (ml/min/1.73 m2) 52.8 92 72.74 ± 10.66
dsDNA (IU/ml) 40 1130 467.60 ± 336.99
C3 (mg/dl) 37 91 62.74 ± 17.39
C4 (mg/dl) 10 31 22.76 ± 4.87
SLEDAI 4 53 28.16 ± 19.91
Cholesterol (mg/dl) 110 431 234.88 ± 94.13
LDL (mg/dl) 105 316 156.12 ± 56.31
HDL (mg/dl) 23 72 40.06 ± 9.69
Triglycerides (mg/dl) 36 220 118.72 ± 64.63
Proteinuria (g/24 h) 0.1 4.8 1.39 ± 1.35
Resistin (ng/ml) 4 21 14.10 ± 3.88
CIMT (mm) 0.2 1.2 0.81 ± 0.46
BMI = body mass index, ESR = erythrocyte sedimentation rate,
CRP= C-reactive protein, Hb%= hemoglobin%, RBCs = red
blood cells, WBCs = white blood cells, GFR= glomerular ﬁltra-
tion rate, SLEDAI = SLE disease activity index, LDL= low
density lipoprotein, HDL= high density lipoprotein, CIMT= -
carotid intima media thickness.
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as regards age, BMI and HDL (p> 0.05), Table 2, Fig. 1.
Comparison between patients with LN and those without LN:
Out of 50 SLE patients, 32 patients had LN (64%) while 18Table 2 Comparison between patients and control groups as regar
Parameter Controls group
n= 40
Mean ± SD
Age (years) 23.36 ± 5.13
BMI (kg/m2) 27.21 ± 0.75
ESR (mm/h) 8 ± 2.47
CRP (mg/dl) 4.12 ± 0.78
Creatinine (mg/dl) 0.75 ± 0.15
Cholesterol (mg/dl) 166.36 ± 9.63
LDL (mg/dl) 106.36 ± 17.5
HDL (mg/dl) 39.38 ± 3.7
Triglycerides (mg/dl) 57.18 ± 15.01
Resistin (ng/ml) 6.44 ± 1.34
CIMT(mm) 0.62 ± 0.11
BMI = body mass index, ESR= erythrocyte sedimentation rate, CRP=
density lipoprotein, CIMT= carotid intima media thickness.
* =Mann-Whitney test (z)SLE patients had no LN (36%). There was a statistically
highly signiﬁcant increase in ESR, CRP, resistin, proteinuria
and disease activity as assessed by SLEDAI in SLE patients
with LN compared to those without LN (p< 0.001). There
was a statistically highly signiﬁcant decrease in serum level
of C3 in SLE patients with LN compared to those without
LN (p< 0.001). There was a statistically signiﬁcant increase
in CIMT and dsDNA in SLE patients with LN compared to
SLE patients without LN (p< 0.05), Table 3, Fig. 1.
Comparison between patients with and without subclinical
atherosclerosis: There was no statistically signiﬁcant difference
in mean serum resistin level in both groups (14.77 ± 2.92 ver-
sus 13.67 ± 4.85 ng/ml) (t 0.983) (p> 0.05).
Comparison between patients with and without arthritis:
There was no statistically signiﬁcant difference in the mean ser-
um resistin level in both groups (p> 0.05).
Correlation studies: Among SLE patients, a signiﬁcant posi-
tive correlation was observed between the serum levels of res-
istin and each of ESR, CRP, creatinine levels, ds-DNA, steroid
duration, disease activity measured by SLEDAI and CIMT
(p< 0.05). A highly signiﬁcant inverse correlation existed be-
tween resistin levels and C3 (p< 0.001), Table 4. Between res-
istin and CIMT after adjustment for BMI still there is a
signiﬁcant positive correlation (p< 0.05), Fig. 2.
4. Discussion
SLE is a prototype of a systemic autoimmune disease of un-
known etiology with skin, joint, renal, cardiovascular and ner-
vous system manifestations. It is characterized by a large
amount of circulating autoantibodies with diverse speciﬁcities
because of abnormal activation of autoreactive B and T-helper
lymphocytes [19]. Patients with SLE have been reported to
have signiﬁcantly higher levels of serum proinﬂammatory cyto-
kines; tumor necrosis factor and interleukin-6 [20]. It has been
shown that resistin can trigger a pro inﬂammatory state
‘‘in vitro’’ as well as ‘‘in vivo’’ [21]. Despite the numerous re-
cent studies concerning resistin pathophysiology, little is
known about how resistin acts in the process of inﬂammation.
It has been demonstrated that proinﬂammatory mediators
such as TNF-a, IL-1b, IL-6, or lipopolysaccharide (LPS) can
strongly increase the expression of resistin in peripheral bloodds clinical, laboratory, carotid duplex examination data.
Patients group
n= 50
Mean ± SD
t or z* p
23.06 ± 6.9 0.246 p> 0.05
27.60 ± 0.71 1.227 p> 0.05
56.74 ± 25.35 13.53 p< 0.001
12.76 ± 3.87 15.467 p< 0.001
1.69 ± 1.09 6.038* p< 0.001
234.88 ± 94.13 5.121 p< 0.001
156.12 ± 56.31 5.967 p< 0.001
40.06 ± 9.69 0.464 p> 0.05
118.72 ± 64.63 6.558* p< 0.001
14.10 ± 3.88 13.202 p< 0.001
0.81 ± 0.46 2.912 p< 0.05
C-reactive protein, LDL= low density lipoprotein, HDL= high
Figure 1 Comparison between SLE patients and control groups.
Y-axis indicates resistin mean serum level ± SD. SLE = Systemic
lupus erythematosus, Neph = Nephritis.
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the process of inﬂammation [21–23].
We found in our study an increase in serum resistin levels in
SLE patients than controls. These ﬁndings came in accordanceTable 3 Comparison between patients with LN and those without
Parameter Patients without
LN (n= 18)
mean ± SD
Age (yrs.) 24.55 ± 9.02
D. D. (yrs.) 2.36 ± 1.20
Systolic (mm Hg) 124.00 ± 18.47
Diastolic (mm Hg) 80.25 ± 8.96
BMI (kg/m2) 27.16 ± 0.75
Steroid dose (mg) 15.75 ± 13.77
Steroid duration (yrs.) 1.58 ± 1.01
ESR (mm/h) 36.65 ± 5.14
CRP (mg/dl) 9.84 ± 1.41
Hb.% (g/dl) 9.04 ± 2.38
RBC (106/mm3) 4.90 ± 2.83
WBC (103/mm3) 5.03 ± 2.42
Platelet (103/mm3) 248.65 ± 82.49
Creatinine (mg/dl) 0.80 ± 0.20
GFR (ml/min/1.73 m2) 75.5 ± 10.9
C3 (mg/dl) 77.60 ± 10.26
C4 (mg/dl) 24.00 ± 4.40
dsDNA (IU/ml) 287.00 ± 247.19
Proteinuria (gm/24 h) 0.29 ± 0.13
SLEDAI 7.50 ± 3.27
Cholesterol (mg/dl) 182.40 ± 41.44
LDL (mg/dl) 133.10 ± 38.69
HDL (mg/dl) 43.15 ± 12.48
Triglycerides (mg/dl) 89.10 ± 51.60
Resistin (ng/ml) 10.75 ± 2.79
CIMT(mm) 0.60 ± 0.37
LN= lupus nephritis, D. D. = disease duration, yrs. = years, BMI = b
reactive protein, Hb%= hemoglobin%, RBCs = red blood cells, WB
DAI = SLE disease activity index, LDL= low density lipoprotein, HDL
* =Mann-Whitney test (z)with other investigators [24,25], but were in contrast with
Chung et al, who showed no difference in resistin levels be-
tween patients and controls [26]. This may be the result of
the greater activity of the disease in our SLE patients. The
mechanism by which resistin is increased in patients with
SLE remains unknown, but postulated explanations include
changes in renal function, direct effect of inﬂammatory medi-
ators on resistin production, alteration in fat distribution or
some combination of these mechanisms [24].
Its role in inﬂammation came in accordance with the corre-
lation we found in our study between serum resistin and each
of ESR and CRP. Almehed et al. stated that markers of
inﬂammation in SLE such as raised ESR, CRP, immunoglob-
ulin G (IgG), proinﬂammatory cytokines, and low S-albumin
levels correlated to resistin in serum [27]. Chung et al, found
a relatively weak association between resistin and ESR but
no association with CRP [26], this may be the result of differ-
ent sample sizes and of the greater activity of disease in our
SLE population. C-reactive protein (CRP) induced both
mRNA expression and protein secretion of resistin in a dose-
and time-dependent manner in PBMCs [28]. Aruna et al. incu-
bated both human and mouse macrophages with human re-
combinant resistin and found increased production of the
proinﬂammatory cytokines TNF-a and IL-12. As the authors
showed, this induction was mediated through the transcription
factor NF-jB, resistin induced dose dependent NF-jB activity
in PBMCs, which resulted in the translocation of both the p65LN.
Patients with
LN (n= 32)
mean ± SD
t or z* p
22.07 ± 5.00 1.122 p> 0.05
2.23 ± 1.29 0.355* p> 0.05
128.00 ± 17.00 0.788 p> 0.05
81.33 ± 9.00 0.418* p> 0.05
27.89 ± 0.76 1.279 p> 0.05
22.67 ± 18.06 1.452* p> 0.05
2.09 ± 1.22 1.562* p> 0.05
70.13 ± 24.59 7.224 p< 0.001
14.70 ± 3.77 6.422 p< 0.001
8.57 ± 1.95 0.751 p> 0.05
3.48 ± 0.85 2.584* p< 0.05
5.27 ± 2.89 0.302 p> 0.05
258.60 ± 70.05 0.458 p> 0.05
2.28 ± 1.03 7.681 p< 0.001
70.91 ± 10.27 1.509 p> 0.05
52.83 ± 13.72 6.882 p< 0.001
21.93 ± 5.06 1.489 p> 0.05
588.00 ± 338.17 3.632* p< 0.001
2.13 ± 1.29 7.788* p< 0.001
41.93 ± 13.13 13.742 p< 0.001
269.87 ± 103.34 4.161 p< 0.001
171.47 ± 61.38 2.710 p< 0.05
38.00 ± 6.76 1.889 p > 0.05
138.47 ± 65.62 2.968* p< 0.05
16.33 ± 2.72 7.039 p< 0.001
0.95 ± 0.46 2.856 p< 0.05
ody mass index, ESR= erythrocyte sedimentation rate, CRP = C-
Cs = white blood cells, GFR= glomerular ﬁltration rate, SLE-
= high density lipoprotein, CIMT= carotid intima media thickness.
Table 4 Correlation between serum resistin and other
variables.
Variable Resistin
r p
Systolic 0.273 p> 0.05
Diastolic 0.266 p> 0.05
BMI 0.036 p> 0.05
Steroid dose 0.153 p> 0.05
Steroid duration 0.293 p< 0.05
ESR 0.631 p< 0.001
CRP 0.667 p< 0.001
Hb% 0.035 p> 0.05
RBC 0.415 p< 0.05
WBC 0.009 p> 0.05
Platelet 0.390 p< 0.05
Creatinine 0.603 p< 0.001
GFR 0.05 p> 0.05
dsDNA 0.413 p< 0.05
C3 0.43 p< 0.001
C4 0.216 p> 0.05
SLEDAI 0.722 p< 0.001
Cholesterol 0.295 p< 0.05
LDL 0.155 p> 0.05
HDL 0.181 p> 0.05
Triglycerides 0.287 p< 0.05
CIMT 0.408 p< 0.05
BMI = Body mass index, ESR= Erythrocyte Sedimentation Rate,
CRP= C-Reactive Protein, Hb%=Hemoglobin%, RBCs = Red
Blood Cells, WBCs =White Blood Cells, GFR=Glomerular ﬁl-
tration rate, SLEDAI = SLE Disease activity index, LDL= low
density lipoprotein, HDL= high density lipoprotein, CIMT= -
Carotid intima media thickness.
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Figure 2 Partial correlation between resistin and CIMT after
adjustment for BMI, (r= 0.348), (p< 0.05). X-axis indicates
CIMT values in mm. Y-axis indicates resistin serum level in ng/ml.
CIMT= Carotid intima media thickness. BMI = Body mass
index.
142 H. Elshishtawy et al.and p50 subunits of NF-jB from the cytoplasm to the nucleus
[23].
Moreover, concerning correlation of serum resistin with
other variables, we found a highly signiﬁcant positive correla-
tion with SLEDAI. However, Baker et al stated that the SLEFigure 3 Histopathological ﬁndings of a female patient in our st
proliferation stained with PSA (PSA ·200). (b) Class III lupus nephr
capsule is seen in the upper right with two parietal epithelial cells in be
body by light microscopy). (EM, Neg., Mag 4600).Disease Activity Index (SLEDAI) was not signiﬁcantly associ-
ated with resistin levels in patients with SLE [24].
Resistin was signiﬁcantly positively correlated to steroid
duration. Almehed et al. found a signiﬁcant correlation be-
tween resistin and steroid use [27]. Due to drug combination
and irregular intake of other drugs we could not investigate
their relation to resistin.
Lupus nephritis is one of the most serious manifestations of
SLE [2]. Our study revealed elevated serum levels of resistin
among SLE patients with LN compared to SLE patients with-
out nephritis. This came in agreement with other investigators
[24,27], who found that renal dysfunction in SLE has beenudy. (a) Class III lupus nephritis with segmental endo-capillary
itis: This shows the constituents of a cellular crescent. Bowman’s
tween, where an apoptotic body is seen (equivalent to hematoxylin
Figure 4 Histopathological ﬁndings of a female patient in our study. (a) Class IV lupus nephritis with global glomerular hypercellularity,
ﬁbro cellular crescent and peri-glomerular ﬁbrosis. There is extensive interstitial inﬂammation, epithelial cells in the tubular lumens, focal
tubular atrophy and thick walled small arteriole. (b) Class IV lupus nephritis: one of the glomerular capillaries shows extensive sub-
endothelial electron dense deposits (SED) consistent with wire loop conﬁguration seen by LM. Extensive SED and a hyaline thrombus
occlude the other capillary in the lower side. Both capillaries showed few scattered sub-epithelial deposits. Glomerular basement
membrane shows splitting and stratiﬁcation. There is a wide fusion of epithelial foot processes. (EM, Neg., Mag 2800).
Figure 6 Histopathological ﬁndings of a female patient in our study. (a) Class IV LN showing positive granular capillary wall and
tubular basement membrane staining for IgG (IgG ·200) (b) Class IV LN showing positive strong (3+) granular mesangial, and faint
capillary wall staining (1+) for IgM (IgM ·200).
Figure 5 Histopathological ﬁndings of a female patient in our study. (a) Class V lupus nephritis, with almost normal mesangial hyper-
cellularity and mild to moderate diffuse thickening of glomerular capillary walls (H&E ·200). (b) Class V nephritis; the glomerular
basement membrane is irregularly thickened with spike formation around multiple sub-epithelial electron dense deposits. Focal intra-
membranous deposits are seen. Parietal cell is swollen with wide fusion of its foot processes. (EM, Neg., Mag., 4600).
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Figure 7 Sonographic measurement of CIMT in a female SLE patient in our study. The double echogenic line on the far arterial wall
represented the carotid intimal medial thickness (CIMT). In (a) CIMT equals 0.4 mm. In (b) CIMT equals 1.2 mm.
144 H. Elshishtawy et al.associated with elevated resistin levels. Malyszko et al., con-
ﬁrmed an association between resistin and renal function
[29], as reported by Nu¨sken et al., in children with CKD on
hemodialysis [12], and previously by Kielstein et al. in a small
cohort of patients with IgA nephropathy [30]. Circulating res-
istin was strongly associated with both GFR and inﬂammatory
biomarkers (hsCRP, IL-6, TNF-a, VCAM and leukocyte
count) in CKD. Due to the low molecular weight of resistin,
it may be expected that the kidneys would be the major secre-
tory pathway for resistin. It has become apparent that CKD is
a state of chronic inﬂammation that is associated with signiﬁ-
cant increases in proinﬂammatory cytokine serum levels at
moderate degrees of renal functional impairment [31]. Yaturu
et al., denoted that resistin levels did not correlate with GFR
[32]. This ﬁnding was in accordance with our results, in con-
trast to the data published by Kielstein et al. [30] who noted
a strong inverse correlation between resistin and GFR; how-
ever their patients represented varied stages of CKD while in
our study we excluded SLE patients on hemodialysis. Yaturu
et al noted a very strong correlation between resistin and
TNF-a, [32]. Increased plasma levels of resistin and CRP in
association with TNF-a suggest a role for resistin as a possible
surrogate marker of inﬂammation in subjects with CKD. Res-
istin has been shown to promote endothelial cell activation and
has been linked to cardiovascular disease in the metabolic
syndrome. Resistin is reported to have a direct effect on vascu-
lar endothelial cells, which is reduced by adiponectin [33].
On comparing SLE patients and the control group, there
was a signiﬁcant increase as regards cholesterol levels, LDL,
triglycerides and CIMT in the patients than the controls. This
may point out that women with lupus are unique in their high
risk of premature atherosclerosis and in the nature of underly-
ing disease process which is chronic vascular inﬂammation [3].
We found in our study a positive correlation between serum
resistin levels and each of CIMT, cholesterol levels and triglyc-
erides. Our results were similar to those of Baker et al who de-
noted elevated resistin levels in SLE patients with coronary
artery calciﬁcation [24]. The earlier ﬁnding by Kougias and
co-workers from their porcine vascular studies showed that
resistin can cause endothelial dysfunction in porcine coronary
arteries through oxidative stress and down-regulation of
eNOS, thus directly contributing to vascular disease [34]. Plas-ma resistin levels have been associated with markers of inﬂam-
mation such as TNF-a, soluble TNF-a receptor-2, or IL-6 and
moreover, resistin has been shown to be a predictive factor for
coronary atherosclerosis in humans, independent of CRP [35].
It was recently shown that resistin correlates with the levels of
biomarkers for cardiac injury, and it has been suggested as a
marker of the severity of myocardium ischemic injury [36].
Resistin was suggested as a mediator of endothelial dys-
function. It has been shown to promote the activation of endo-
thelial cells via the release of endothelin (ET-1). Furthermore,
it induces the expression of vascular cell adhesion molecule
(VCAM-1), inter-cellular adhesion molecule 1 (ICAM-1), vas-
cular endothelial growth factor receptors (VEGFR), matrix
metalloproteinases (MMPs), and MCP-1. Resistin can target
several human cells, thereby enhancing inﬂammatory and
autoimmune processes. It induces endothelial cell growth and
migration, which are involved in angiogenesis. Together with
a glucose-dependent increase in triglyceride and cholesterol
cellular mass in macrophages, it can contribute to the process
of atherosclerosis and its related complications. It has been
demonstrated that patients with chronic kidney disease have
an increased risk of athero-thrombosis [37].
In conclusion, serum level of resistin may serve as a marker
of LN and atherosclerosis in SLE patients. A more aggressive
control of the underlying inﬂammatory process along with the
control of traditional risk factors (hypertension and choles-
terol) may be beneﬁcial in reducing the risk factors of renal
and atherosclerotic involvement in SLE. Therapeutic ap-
proaches with drugs that target resistin might be useful in
the treatment of SLE.
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